7 Analytical comparison of a PD-L1 22C3 antibody laboratory-developed test protocol on the Benchmark XT and PD-L1 IHC 22C3 pharmDx: pan-tumor and triple-negative breast cancer samples

• Lingkang Huang,
• Kenneth Emancipator,
• Gilad Vainer,
• Ghadeer Zatara,
• Shanthy Nuti

Affiliations

Lingkang Huang

3 Merck & Co., Inc, Kenilworth, New Jersey, USA

Kenneth Emancipator

Merck and Co., Inc., Kenilworth, NJ, USA

Gilad Vainer

1Hadassah–Hebrew University Medical Center, Jerusalem, Israel

Ghadeer Zatara

1Hadassah–Hebrew University Medical Center, Jerusalem, Israel

Shanthy Nuti

2Merck and Co., Inc., Westfield, NJ, USA